GDTC: Prakiraan gabungan firma investasi CytoMed Therapeutics

The stock price retrospective for CytoMed Therapeutics (GDTC) demonstrates the dynamics of a company developing affordable, universal CAR-T therapy based on allogeneic T-cells. The business is implementing automated bioreactors that eliminate human error during drug synthesis, which is recorded at the level of 4.16. However, financial stability is constrained by manufacturing complexities, patent conflicts, and the probability of failures during clinical trials.

GDTC - Prakiraan konsensus analis CytoMed Therapeutics Ltd ing rentang 21.02.2024 - 22.10.2026

Rincian analitis perusahaan CytoMed Therapeutics (GDTC)

Indikator analitis utama w2.cytomed.sg (GDTC):

Bagan kurs w2.cytomed.sg|GDTC - Prakiraan konsensus analis|Kapitalisasi pasar CytoMed

Analisis fundamental perusahaan:CytoMed Therapeutics Ltd (GDTC)

Produk asli CytoMed Therapeutics

High demand for innovative cancer treatments within the allogeneic therapy segment drives the capitalization potential of CytoMed Therapeutics (GDTC). The weighted average of target prices, aggregating expert expectations for the business's fundamental value, reflects the market consensus regarding the issuer's prospects, allowing the change in the average target price to be tracked as an indicator of the asset's shifting investment attractiveness.

Perusahaan pesaing

beigene.com (ONC) - Rentang target analis|Prakiraan konsensus analis HALO (Halozyme)|RVMD: Prakiraan gabungan firma investasi|AAPG: Target konsensus|CG Oncology Therapeutics - Rega prakiraan analis|URGN: Prakiraan konsensus analis|Target konsensus bicara.com|PSNL (Personalis) - Prakiraan konsensus analis|Target konsensus Erasca Inc (ERAS)|Prakiraan konsensus analis DCTH|Prakiraan konsensus analis Y-mAbs Corp (YMAB)|Bagan rega target Aura Biosciences, Inc. AURA|CADL: Prakiraan gabungan firma investasi|Accuray - Prakiraan konsensus analis|SELLAS Life Sciences (SLS) - Target konsensus|ACTU: Prakiraan konsensus analis|Rata-rata rega prakiraan Citius Oncology Inc (CTOR)|Bagan rega target TuHURA Biosciences Inc.|TARA: Konsensus nilai wajar|Target konsensus FATE (Fate Therapeutics)|WHWK (aadibio.com) - Konsensus nilai wajar|Prakiraan konsensus analis TCRX (TScan Therapeutics, Inc.)|CSBR - Target konsensus|XBIT: Target konsensus|CVM - Prakiraan konsensus analis|OS Therapies (OSTX) - Bagan rega target|Radiopharm Theranostics Ltd - Konsensus nilai wajar|ARTV (Artiva Biotherapeutics Inc.) - Prakiraan konsensus analis|Rata-rata rega prakiraan Adlai Nortye Limited ANL|Prakiraan konsensus analis VERU|Target konsensus tempesttx.com TPST|Xilio Therapeutics - Target konsensus|Renovaro Biosciences (RENB) - Rata-rata rega prakiraan|MURA: Target konsensus|Kairos Pharma Ltd - Rega prakiraan analis|onkuretherapeutics.com (OKUR) - Bagan rega target|Rata-rata rega prakiraan Curis (CRIS)|Bagan rega target Apollomics Inc.|Target konsensus Tharimmune Inc (THAR)|Prakiraan konsensus analis ADVB|GNPX - Rata-rata rega prakiraan|Prakiraan konsensus analis CLDI (Calidi Biotherapeutics, Inc.)|SBFM: Prakiraan gabungan firma investasi|XBIO: Target konsensus|Konsensus nilai wajar SLRX (Salarius Pharmaceuticals Inc)|PPBT (Purple Biotech Corp) - Target konsensus|AONC: Rega prakiraan analis|BGNE (BeiGene, Ltd.) - Prakiraan konsensus analis|CKPT: Konsensus nilai wajar|Prakiraan konsensus analis ELEV|ICAD - Rata-rata rega prakiraan|Bagan rega target Ikena Oncology IKNA|Konsensus nilai wajar NTBL|Viracta - Prakiraan konsensus analis|MOR - Prakiraan konsensus analis|NAYA Biosciences Inc. (NAYA) - Bagan rega target|Bagan tingkat prakiraan AAPGV (Ascentage Pharma Group International)